- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Google's Calico Partners with Ancestry.com to Access Genetic Database
Calico, a longevity company backed by Google (NASDAQ:GOOGL), has partnered with Ancestry.com (NASDAQ:ACOM) to access more than 1 million DNA samples from the company.
Calico, a longevity company backed by Google (NASDAQ:GOOGL), has partnered with Ancestry.com (NASDAQ:ACOM) to access more than 1 million DNA samples from the company.
According to the Bloomberg Business article:
AncestryDNA, a division of the Provo, Utah-based genealogy company, has gathered more than 1 million DNA samples from the $99 testing kits it sells to consumers to help map their family history. Beside the genetic information, Calico will have access to tens of millions of public family trees created by consumers, which include birth and death dates, relationships, and geographical locations.
Health companies are mining the growing amounts of digital information on people’s genetic codes to hunt for clues about how diseases develop — and how they might be cured or prevented. Databases are growing as costs fall as low as $1,000 to sequence a whole genome, while selective genotyping is even cheaper.
Â
Click here to read the full article on Bloomberg Business.
Â
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â